#United States #Milpitas #Galaxy Therapeutics #SEAL device #WNBA treatment

Galaxy Therapeutics Submits Final PMA for SEAL™ Device

In a significant development for the medical community, Galaxy Therapeutics has announced the submission of its final module of the Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) regarding its innovative SEAL™ device. This device is specifically designed for treating wide-neck bifurcation aneurysms (WNBA), a complex and often dangerous condition in neurosurgery.

Founded by a group of neurointerventional physicians, Galaxy Therapeutics is on the cutting edge of techniques designed to combat brain aneurysms. The recent submission is fortified with comprehensive data from the SEAL IT IDE trial, which included 163 patients and was conducted across several leading neurointerventional centers in the United States. This pivotal trial focused on real-world applicability, examining a diverse range of aneurysm sizes and anatomical characteristics. Furthermore, it represents one of the most extensive prospective studies in the realm of intracranial aneurysms, with dedicated groups assessing various types of aneurysms, including wide-neck bifurcation, sidewall, and ruptured aneurysms.

Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed pride in reaching this major milestone. “Submitting the final PMA module for SEAL represents a significant step forward in our commitment to delivering advanced solutions for treating complex brain aneurysms,” he stated. This submission marks not only a personal achievement for the company but also a hopeful future for patients requiring these critical interventions.

Jim Twitchell, the Chief Operating Officer, echoed this sentiment, acknowledging the collaborative effort across clinical, manufacturing, and regulatory teams. “The successful execution of our processes has established the foundation for supporting upcoming growth phases and achieving future commercialization objectives,” he commented. It signals a robust infrastructure ready to handle the ongoing challenges of bringing innovative solutions to market.

Looking ahead, Galaxy Therapeutics is poised to maintain a close partnership with the FDA throughout the review process of their PMA. Such collaborations are crucial as they navigate the regulatory landscape to achieve approval, ensuring that their advanced treatment options can soon be accessible to those in dire need.

About Galaxy Therapeutics

Galaxy Therapeutics stands out as a U.S.-based clinical-stage medical device company with a mission focused on addressing life-threatening medical conditions, particularly brain aneurysms. They combine clinical expertise and innovative technology, holding multiple patents in the U.S., EU, China, and other significant markets. Headquartered in Milpitas, California, the company is dedicated to reforming treatment methods and spreading an awareness of the importance of addressing complex brain aneurysms effectively.

For more details about Galaxy Therapeutics and their groundbreaking work, please visit their official website at www.galaxytherapeutics.com or look for them on LinkedIn. Emphasizing that the SEAL device is currently classified as investigational, this innovation underscores the company's commitment to regulatory compliance and patient safety in their upcoming endeavors.